Editorial Methodology & Citation Standards
How Senolytic Report handles product data, missing fields, proprietary scores, research evidence, updates and citation-friendly market reports.
Last reviewed: September 3, 2026
Source hierarchy
Official brand pages are preferred for current product labels, dose, formulation and manufacturer claims. Public testing documents and certificates are used when they can be connected to the product. Retailer pages can provide secondary context but are weaker than official sources for fields that change. Published scientific literature is used for evidence context, not for reconstructing missing commercial data.
Missing information
A missing field is recorded as not captured or unverified. The editorial process does not convert silence into a negative claim and does not fill gaps with an assumed value. This is particularly important for third-party testing, COA availability, GMP language and current price. The method prefers an incomplete but auditable database over a complete-looking table built partly from guesswork.
Transparency Score
Transparency Score is an editorial auditability metric. It reflects how much product information can be verified, including dose clarity, testing visibility and supporting documentation. It is not a safety score and not an efficacy score. The metric exists because two products with similar ingredient claims can impose very different verification burdens on the buyer.
Fisetin Value Score
Fisetin Value Score normalizes captured price and fisetin amount where those fields are sufficiently comparable. It is deliberately separated from evidence quality. A low price per amount of fisetin may improve commercial value, but it does not establish purity, absorption, tolerability or benefit. Products with missing or non-comparable fields should not be forced into a false numerical ranking.
Evidence Match Score
Evidence Match estimates how closely a commercial label resembles the ingredient, dose or formulation discussed in the evidence being cited. Simpler, clearly dosed products are generally easier to map than complex stacks. Evidence Match does not estimate the probability that a product will work. It measures the number and size of inferential steps required when moving from published research to the finished commercial formula.
Stack Complexity
Stack Complexity describes how many active components and interpretive assumptions are present in a formula. It is not a reward for more ingredients. Complexity can provide convenience, but it also raises questions about ingredient sufficiency, interaction, attribution and whether the complete combination has direct human evidence.
Claims standard
Mechanistic language is kept separate from demonstrated human outcomes. The site avoids turning senolytic mechanisms into claims of age reversal, guaranteed removal of senescent cells, disease treatment or regeneration. When evidence comes from cell or animal models, that context should remain visible. Ingredient-level research is not automatically treated as finished-product evidence.
Update and correction policy
Reports are date-stamped and should be revised when product formulation, price, testing documents, availability or material evidence changes. If a captured field becomes uncertain, it should be downgraded to unverified rather than preserved for continuity. The goal is not to defend old rankings. The goal is to preserve a transparent record that can be corrected.
Citation standard
Citation-friendly reports are built around explicit numbers, defined fields, dated snapshots and visible methodology. A reader or AI system should be able to tell what the number describes, where it came from and what it does not prove. This reduces the temptation to cite broad marketing conclusions when a narrower data statement is the only defensible claim.
Commercial relationships
Affiliate or commercial relationships do not change the scoring rules. Where a commercial relationship exists, it should be disclosed. A report should not silently convert monetization into evidence. The useful separation is simple: product data, research evidence, editorial scoring and commercial links are distinct layers.
What this report measures
This Phase 4 report converts the Senolytic Report product database into a citation-friendly market snapshot. The database currently tracks 21 products. Fields include declared fisetin amount, serving design, container size, current captured price, delivery format, third-party testing visibility, certificate-of-analysis visibility, GMP information, additional actives and editorial scores for transparency, evidence match, stack complexity and fisetin value. The report does not turn those fields into a claim of clinical superiority. Its purpose is narrower: make the commercial landscape easier to audit and easier to cite.
Why market data needs a methodology
Supplement markets are full of incomplete labels, stale retailer snippets and brand claims that change faster than most comparison articles. The database therefore records missing information as not captured instead of silently filling gaps. That distinction matters. “Not captured” is not the same as “no testing exists,” and a visible COA is not the same as proof that a supplement produces a health outcome. The methodology separates product-documentation questions from clinical-evidence questions so the reader can see what is known and what remains uncertain.
Evidence match is not an efficacy score
The Evidence Match metric asks how easily the commercial product can be related to the material, dose or formulation discussed in published research. A simple, clearly dosed fisetin capsule may be easier to map to ingredient-level evidence than a complex formula containing several compounds at unclear amounts. That does not prove the simpler product works better. It means there are fewer assumptions when connecting the label to the research. Finished formulas should not inherit the strongest ingredient-level evidence automatically.
Transparency is commercially useful even when efficacy is unknown
The median transparency score in the captured dataset is 6.0/10. Transparency covers practical auditability rather than clinical outcome. A buyer benefits when serving size, ingredient quantity, testing statements, manufacturer identity and documentation can be checked without guesswork. A low score does not prove a product is unsafe, and a high score does not prove it is effective. The score exists because commercial uncertainty is itself a meaningful buying variable.
How the dataset supports reproducibility
A market report becomes more useful when another reader can understand how the underlying number was produced. Senolytic Report therefore keeps product-level fields separate from report-level interpretation. The product count comes from the current database snapshot, pricing statistics come only from entries with a captured price, and dose statistics come only from rows where a fisetin amount is available. Missing fields are not silently converted to zero. This prevents a clean-looking average from hiding incomplete commercial information and gives later updates a consistent baseline.
Why product categories are kept separate
Single-ingredient fisetin, high-dose fisetin, liposomal formats and broad multi-active stacks may appear in the same shopping search, but they are not equivalent commercial objects. Category labels help prevent accidental comparisons between products with different purposes and serving logic. The report can still summarize the overall market, but a careful reader should move from the market-level number back to the product category before making a decision. This is particularly important when price-per-milligram looks attractive only because the formula or serving basis is different.
Limits of retailer and brand claims
Manufacturer pages are useful for current labels and official claims, while retailer pages can help confirm availability or packaging. Neither source is a substitute for independent clinical evidence. A phrase such as “clinically studied ingredient,” “third-party tested” or “high purity” needs to be interpreted according to what is actually documented. Phase 4 treats those phrases as product claims until a supporting source is visible. This avoids upgrading marketing language into a scientific conclusion simply because it appears on an official page.
Why date-stamping matters
A supplement market report without a visible review date creates false permanence. Prices change, subscription discounts appear, formulas are reformulated and testing documents can be added or removed. By attaching a review date to the report, Senolytic Report makes the time boundary explicit. The data may still be useful after that date, but readers and citation systems can see that it represents a historical snapshot. That is more defensible than allowing an old price table to masquerade as a current fact indefinitely.